FDA Thwarts Leo Pharma's US Launch Plans For Tralokinumab
Agency Issues CRL For Atopic Dermatitis Drug
A week after getting the thumbs-up from the CHMP for tralokinumab, the Denmark-based dermatology specialist has been hit by a complete response letter from US regulators requesting more data about a device component of the IL-13 inhibitor.
